BMD4503-2 [CAS 301357-87-9]

BMD4503-2 is a quinoxaline derivative with inhibitory activity against LRP5/6-sclerostin interactions. BMD4503-2 restores the activity of the Wnt/β-catenin signaling pathway by competitively binding to the LRP5/6-sclerostin complex. BMD4503-2 can be used in the study of Wnt signaling pathways in bone development, maintenance and osteoporosis[1].

[301357-87-9]

C26H21N5O3S

483.54

CC(NC1=CC=C(C=C1)S(=O)(NC2=NC3=CC=CC=C3N=C2NC4=C5C=CC=CC5=CC=C4)=O)=O

Others

99.21

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature